SecBot SecBot
Biotech Drug Report Generated Aug 1, 2026

DYNE-302

DYN·Dyne Therapeutics, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Not stated
Time to market
unknown, no clinical trial, FDA, or company disclosure record for DYNE-302 could be verified this session; absence from ingested ClinicalTrials.gov/FDA data suggests it is at most an early/preclinical-stage program, but this cannot be confirmed.
Why 2/10
No hard, dated catalyst for DYNE-302 exists in the next ~12 months, no trial, FDA, or press records for the drug were found in any source this session, and Dyne's actual binary catalysts (z-rostudirsen PDUFA Jan 21, 2027; z-basivarsen ACHIEVE topline Q1 2027) belong to other programs, so DYNE-302 is at most a minor, unverifiable early-stage program.
Actionable Insight NEUTRAL

Near-term DYN moves will be driven by z-rostudirsen's PDUFA (Jan 21, 2027) and z-basivarsen's Q1 2027 topline, not by this program.

Price Chart

Loading chart...

Executive Summary

DYNE-302 is a drug code attributed to Dyne Therapeutics (Nasdaq: DYN), a clinical-stage neuromuscular biotech confirmed via SEC-derived records. Dyne's stock value is instead carried by z-rostudirsen (DMD exon 51; BLA accepted with Priority Review, PDUFA Jan 21, 2027) and z-basivarsen (DM1; ACHIEVE topline expected Q1 2027). With no evidence of a scheduled catalyst, clinical data, or even confirmed public disclosure for DYNE-302, the drug rates neutral with minimal standalone impact on DYN.

How It Works

Not verifiable from any source retrieved this session. By context, Dyne Therapeutics builds therapies that target disease-causing genes' RNA in muscle cells using antisense oligonucleotide technology, its confirmed programs z-rostudirsen (DYNE-251, DMD exon-51 skipping) and z-basivarsen (DYNE-101, DM1) work this way, so DYNE-302 is presumed to be a similar antisense-based candidate in Dyne's neuromuscular pipeline, but its specific target and mechanism are unconfirmed.

Trial Status

No trial records found. SecBot's ingested ClinicalTrials.gov data (ticker DYN, drug "DYNE") and FDA catalyst/trial data contain zero entries for DYNE-302; the only DYNE-matched trial record is an unrelated Colgate dental study (NCT06244290). DYNE-302 does not appear in any of Dyne's press releases or SEC filings indexed locally either.

The Two-Sided Case

▲ Bull Case4
Developer is a confirmed, well-covered Nasdaq name: Dyne Therapeutics (DYN) has 18 of 21 analysts at Buy/Strong Buy with a mean price target of $39.53 versus a ~$25.18 price (implied upside ~58.9%) per SecBot's 2026-07-31 analyst snapshot.
Dyne has deep cash: it raised $375.15M gross in a July 2026 upsized offering and expanded its credit facility to $400M, with runway into Q2 2028 per its Q2 2026 release, so an early-stage program like DYNE-302 would be well funded.
If DYNE-302 is a next platform program (by naming convention after DYNE-101/DYNE-251), it would ride Dyne's established muscle-targeted antisense delivery platform, which has already produced positive data in DMD (DELIVER trial) and a completed-registrational-cohort DM1 trial.
DYN traded near its 52-week high ($26.26) at $25.18 as of 2026-07-31, with recent analyst price-target upside, overall sentiment toward the company is bullish independent of DYNE-302.
▼ Bear Case4
No scheduled binary catalyst: the next hard dates for DYN (z-rostudirsen PDUFA 2027-01-21; z-basivarsen topline Q1 2027) belong to other drugs; DYNE-302 has no dated catalyst in the next ~12 months.
If it is early-stage/preclinical, it carries typical development risk, no clinical data exists to evaluate efficacy or safety, and it contributes nothing to near-term value.
Shareholder dilution: Dyne sold 18.3M shares at $20.50 in July 2026 (about 9-11% dilution per press analysis) and insiders have been selling (e.g., director Kersten Dirk sold ~$6.5M of stock on 2026-07-27 under a 10b5-1 plan).
Elevated bearish positioning: FINRA short-volume flow on DYN ranged roughly 56-74% of off-exchange volume on multiple days in July 2026, indicating heavy shorting/hedging interest.

Upcoming Catalysts

  • z-rostudirsen (DYNE-251) PDUFA target action date, Jan 21, 2027 (Priority Review BLA, DMD exon 51)
  • z-basivarsen (DYNE-101) ACHIEVE registrational topline data, expected Q1 2027 (DM1)
  • Any future Dyne pipeline/R&D update or disclosure that could confirm DYNE-302's target, phase, and IND timeline

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Dyne Therapeutics, Inc. PRESS-RELEASE DYN ·Originating report

Sources · 6

Hover a chip for the title
1 globenewswire.com2 globenewswire.com3 globenewswire.com4 sec.gov5 sec.gov6 sec.gov